Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Akero Therapeutics Inc (AKRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: AKRO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 50.43% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.40B USD | Price to earnings Ratio - | 1Y Target Price 77.64 |
Price to earnings Ratio - | 1Y Target Price 77.64 | ||
Volume (30-day avg) 948674 | Beta -0.2 | 52 Weeks Range 17.86 - 58.40 | Updated Date 03/31/2025 |
52 Weeks Range 17.86 - 58.40 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.37% | Return on Equity (TTM) -39.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2515605580 | Price to Sales(TTM) - |
Enterprise Value 2515605580 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.77 | Shares Outstanding 79620096 | Shares Floating 66404779 |
Shares Outstanding 79620096 | Shares Floating 66404779 | ||
Percent Insiders 2.34 | Percent Institutions 93.6 |
Analyst Ratings
Rating 4.55 | Target Price 48.27 | Buy 3 | Strong Buy 7 |
Buy 3 | Strong Buy 7 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Akero Therapeutics Inc
Company Overview
History and Background
Akero Therapeutics, Inc. is a biotechnology company founded in 2017. It focuses on developing treatments for non-alcoholic steatohepatitis (NASH) and other metabolic diseases. The company has progressed rapidly with its lead drug candidate, efruxifermin (EFX).
Core Business Areas
- Drug Development: Focuses on developing and commercializing therapeutic candidates for NASH and other metabolic diseases.
Leadership and Structure
Dr. Andrew Cheng is the CEO. The company has a typical organizational structure for a biotech company with teams focused on research, clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Efruxifermin (EFX): EFX is Akero's lead drug candidate for the treatment of NASH. It is a fibroblast growth factor 21 (FGF21) analog. EFX is currently in phase 2b and phase 3 clinical trials. It does not yet have market share as it is not approved yet. Competitors include Madrigal Pharmaceuticals and Viking Therapeutics who also have NASH drugs in the clinical pipeline.
Market Dynamics
Industry Overview
The NASH market is a large and growing market with no currently approved therapies. It is driven by the increasing prevalence of obesity and diabetes. Many companies are pursuing drug development in this area.
Positioning
Akero is positioned as a key player in the NASH market with its lead drug candidate, EFX. EFX has shown promising results in clinical trials so far which gives the company a strong position in the market.
Total Addressable Market (TAM)
The estimated TAM for NASH is tens of billions of dollars. Akero is targeting a significant share of this market if EFX gets approved.
Upturn SWOT Analysis
Strengths
- Promising clinical trial results for EFX
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Reliance on a single drug candidate
- Lack of established commercial infrastructure
- High cash burn rate
Opportunities
- Potential approval of EFX
- Expansion into other metabolic diseases
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from other NASH drugs
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
Competitive Landscape
Akero is in competition with Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX). Due to the fact that there are no current drugs on the market, none of the competitors have market share for NASH. Akero's advantage lies in EFX and results from clinical trials.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Akero's historical growth is characterized by significant R&D investment and clinical trial progress. Since they are still in trials, there are no sales.
Future Projections: Future growth depends on the success of EFX in clinical trials and regulatory approval. Analyst estimates vary widely based on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing EFX through phase 2b and 3 clinical trials, expanding partnerships, and exploring additional metabolic disease targets.
Summary
Akero Therapeutics is a clinical-stage biotech company focused on developing therapies for NASH. Its lead drug candidate, EFX, has shown promising results and could be a significant player in the market if approved. The company is still reliant on a single drug and faces the risks associated with clinical trials. However, the company has an opportunity for strong growth if EFX is successful and it can grow to compete with the other companies in the market.
Similar Companies
- MDGL
- VKTX
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The data provided is based on available information and may be subject to change. This is not financial advice. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akero Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-06-20 | President, CEO & Director Dr. Andrew Cheng M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 63 | Website https://akerotx.com |
Full time employees 63 | Website https://akerotx.com | ||
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.